Rare Diseases and Orphan Products

Institute of Medicine

135 citations0/0 files storedNational Academies Press eBooks

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Genomics and Rare Diseases Biomedical Ethics and Regulation

Abstract

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 135 citations exist upstream.

Cited by

2014Orphan drugs policies: a suitable case for treatment 2012Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry 2018Orphan Drugs and Their Impact on Pharmaceutical Development 2018The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs 2021How rare is rare? A literature survey of the last 45 years of paleopathological research on ancient rare diseases

Imported from OpenAlex (CC0) — nothing here is generated.